Latest

Lower Respiratory Tract Infection: Symptom Duration and Severity With Oral Prednisolone

Lower Respiratory Tract Infection: Symptom Duration and Severity With Oral Prednisolone

Oral corticosteroids did not reduce symptom severity or duration in patients with lower respiratory tract infections without asthma.

New Biomarker May Enable Selective Antibiotic Use for COPD Exacerbation

New Biomarker May Enable Selective Antibiotic Use for COPD Exacerbation

Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.

Does Targeted Inflammation Therapy Reduce Risk of CV Events, Lung Cancer?

Does Targeted Inflammation Therapy Reduce Risk of CV Events, Lung Cancer?

Canakinumab vs placebo showed promising results in preventing recurrent cardiovascular events and incidences of lung cancer.

Expert Panel Updates Recommendations for Endoscopic Lung Volume Reduction for Emphysema

Expert Panel Updates Recommendations for Endoscopic Lung Volume Reduction for Emphysema

Advanced emphysema may benefit from endoscopic lung reduction treatment.

Smoking Cessation Advice Before Cosmetic Surgery Making Lead to Long-Term Quitting

Smoking Cessation Advice Before Cosmetic Surgery Making Lead to Long-Term Quitting

Asking patients to stop smoking before undergoing cosmetic surgery can promote long-term smoking cessation with 40.5% of participants in a recent study no longer smoking on a daily basis.

Reduced Mortality Risk in COPD Linked to Statin Tx

Reduced Mortality Risk in COPD Linked to Statin Tx

People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.

COPD Exacerbations May Be Reduced With Mucolytic Agents

COPD Exacerbations May Be Reduced With Mucolytic Agents

Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.

Racial Differences in ARTI Treatment Received in Pediatric Emergency Departments

Racial Differences in ARTI Treatment Received in Pediatric Emergency Departments

The correlation between patient race and ethnicity and administration of antibiotic treatment for viral acute respiratory tract infections was examined.

Addressing Asthma Exacerbations Via Sputum Eosinophils vs Clinical Symptoms

Addressing Asthma Exacerbations Via Sputum Eosinophils vs Clinical Symptoms

Adults with asthma benefit from tailoring interventions based on sputum eosinophils vs clinical symptoms.

Inappropriate Use of Short Acting Beta Agonists Linked to Adverse Outcomes

Inappropriate Use of Short Acting Beta Agonists Linked to Adverse Outcomes

Researchers analyzed over 2.1 million patient-years' worth of data to determine the impact of short-acting beta agonist use in asthma.

Tezepelumab Tx in Asthma: Does Treatment Reduce Exacerbations?

Tezepelumab Tx in Asthma: Does Treatment Reduce Exacerbations?

Participants received 70 mg of tezepelumab every 4 weeks throughout the study.

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.

Efficacy of Tiotropium in Mild to Moderate COPD Examined

Efficacy of Tiotropium in Mild to Moderate COPD Examined

FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.

FDA: Priority Review for Alectinib for ALK-positive NSCLC

FDA: Priority Review for Alectinib for ALK-positive NSCLC

Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.

Nasal Spray Availability Impacts Pediatric Influenza Vaccination Rates

Nasal Spray Availability Impacts Pediatric Influenza Vaccination Rates

Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.

Steroid-Resistant Asthma: Exploring New Therapeutic Possibilities

Steroid-Resistant Asthma: Exploring New Therapeutic Possibilities

The pathogeneses of steroid insensitivity in severe, steroid-resistant asthma may unlock new potential treatments.

Once-Daily Fluticasone Furoate/Vilanterol Reduces Nighttime Asthma Symptoms

Once-Daily Fluticasone Furoate/Vilanterol Reduces Nighttime Asthma Symptoms

Fluticasone furoate and vilanterol combination therapy reduced both daytime and nighttime symptoms in patients with persistent uncontrolled asthma.

Acute Lower Respiratory Infection Risk In Infants Impacted by Maternal Vaccination

Acute Lower Respiratory Infection Risk In Infants Impacted by Maternal Vaccination

Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.

Sign Up for Free e-newsletters